Inclusion Criteria:

- Signed informed consent

- Age ≥ 18 years

- Histologically confirmed CRC with evidence of metastases and measurable tumor lesions

- Documented disease progression following, or intolerance to, treatment with
5-fluorouracil, oxaliplatin, and bevacizumab-based therapy

- Life expectancy > 3 months

- For patients of reproductive potential (males and females), use of reliable means for
contraception (e.g., contraceptive pill, intrauterine device [IUD], physical barrier)
throughout the trial and for 6 months following their final exposure to study
treatment

- Willingness and capability to be accessible for study follow-up

Exclusion Criteria:

- Patients who have a Kras mutation will be excluded from receiving
cetuximab-containing regimens

- Prior radiotherapy to a measurable metastatic lesion(s) to be used for response
assessment, unless the lesion has progressed subsequent to the radiotherapy

- Recent radiotherapy to a peripheral lesion, thoracic, abdominal, or pelvic field

- Recent chemotherapy, hormonal therapy, or immunotherapy

- Evidence of clinically detectable ascites

- Other invasive malignancies within 5 years

- History or evidence of active central nervous system (CNS) disease

- Current or recent participation in another experimental drug study

- Clinically significant cardiovascular disease

- Active infection requiring parenteral antibiotics

- Recent major surgical procedure, open biopsy, significant traumatic injury, fine
needle aspirations, or anticipation of need for major surgical procedure during the
course of the study

- Known or suspected to be positive for the human immunodeficiency virus (HIV)

- Known to be positive for hepatitis C or hepatitis B surface antigen

- History of other disease, metabolic dysfunction, physical examination finding, or
clinical laboratory finding giving reasonable suspicion of a disease or condition
that contraindicates use of an investigational drug or specified study treatment

- Pregnancy (positive pregnancy test) or breast feeding

- Serious, non-healing wound, ulcer, or bone fracture

- Known sensitivity to any of the products administered during the study

- Any disorder that compromises the ability of the patient to provide written informed
consent and/or comply with study procedures